Helping You Build Wealth With Honest Research
Since 1996. Try Now

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Indian share markets open firm
Fri, 30 Nov 09:30 am

Barring Indonesia (down 0.4%), the other major stock markets in Asia have opened the day on a firm note with stock markets in Taiwan (up 1%) and Singapore (up 1%) leading the gains. The Indian share market indices have also opened the day on a firm note. Stocks in the consumer durables, realty and metal space are leading the gains. However, FMCG and auto stocks are trading weak.

The Sensex today is up by around 59 points (0.3%), while the NSE-Nifty is up by around 24 points (0.4%). Mid and small cap stocks are also trading in the green with the BSE Mid Cap and BSE Small Cap indices up by around 0.7% and 0.5% respectively. The rupee is trading at Rs 54.44 to the US dollar.

Telecom stocks have opened the day on a firm note with Bharti Airtel, Reliance Communications and Mahanagar Telephone Nigam Ltd (MTNL) trading firm. As per a leading financial daily, India's leading telecom services provider is set to launch the initial public offering (IPO) of Bharti Infratel, its telecommunications tower unit. The offering is expected to comprise 188.9 m shares or 10% of the Bharti Infratel's equity capital. The issue, which will be launched on 11 December 2012 and close on 14 December 2012, is likely to raise up to US$ 825 m. This would make it the biggest IPO in the country over the last two years. As per the daily, the company is expected to set a per share price band of Rs 210 to Rs 240 for the IPO. It must be noted that the company is yet to make an official announcement.

Indian pharma stocks have also opened the day on a firm note with Divi's Laboratories, Cipla and Glenmark Pharmaceuticals leading the gains. As per a leading financial daily, Glenmark Pharmaceuticals expects its revenues to grow by about 25-30% to touch Rs 50 bn during the financial year 2012-13 (FY13). The company's Chairman and Managing Director stated that the US, which has been an important market for the company, will continue to remain a key growth market. In addition, Latin America is another focus area for the drug maker and is expected to be an important growth driver. The Mumbai-based company already markets 82 products in the US market. Another 40 products are awaiting approval from the United States Food and Drug Administration (USFDA). It must be noted that during the financial year 2011-12 (FY12) the company had reported revenues of about Rs 40 bn. Nearly 75% of revenues are contributed by the international market, while about 25% come in from the domestic market.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Indian share markets open firm". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Agora Research Private Limited.

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Agora Research Private Limited (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.